NEBUPENT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nebupent, and when can generic versions of Nebupent launch?
Nebupent is a drug marketed by Fresenius Kabi Usa and is included in one NDA.
The generic ingredient in NEBUPENT is pentamidine isethionate. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentamidine isethionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nebupent
A generic version of NEBUPENT was approved as pentamidine isethionate by SETON PHARMS on September 28th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEBUPENT?
- What are the global sales for NEBUPENT?
- What is Average Wholesale Price for NEBUPENT?
Summary for NEBUPENT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,663 |
| What excipients (inactive ingredients) are in NEBUPENT? | NEBUPENT excipients list |
| DailyMed Link: | NEBUPENT at DailyMed |
Recent Clinical Trials for NEBUPENT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Illinois at Chicago |
Pharmacology for NEBUPENT
| Drug Class | Antiprotozoal |
US Patents and Regulatory Information for NEBUPENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | NEBUPENT | pentamidine isethionate | FOR SOLUTION;INHALATION | 019887-001 | Jun 15, 1989 | AN | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Fresenius Kabi Usa | NEBUPENT | pentamidine isethionate | FOR SOLUTION;INHALATION | 019887-002 | Mar 22, 1996 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
